May 31, 20221 min read, 271 words
Published: May 31, 2022 | 1 min read, 271 words
Buying 500 shares of Daiichi Sankyo stock 16 days before the company signed a lucrative licensing deal with AstraZeneca has a former AZ executive in the Securities and Exchange Commission's (SEC's) crosshairs.
According to an SEC complaint, Hugues Joublin, Ph.D.—who was AZ’s glo...
No article scores yet.
There are no critic or public scores for this article yet.
Investigative2
critic score
0 reviews
public score
2 reviews
critic score
0 reviews
public score
2 reviews
CRITIC REVIEWS
There don't seem to be any reviews yet.
PUBLIC REVIEWS
Investigative
Jun 1
I am glad the people that have been charged with trying to take advantage of biopharma M&A activities with stock purchases are finally being exposed.
Jun 1
Investigative
Jun 1
This is just one of several examples of crooks trying to take advantage of biopharma M&A activities with stock purchases.
Jun 1